Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, Orionis Biosciences is raising $55,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Nikolai Kley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Orionis Biosciences
Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our technologies and pipeline include proprietary A-Kine biologics and Allo-Glue small molecule platforms with broad, innovative applications to the reprogramming of disease states. The company is currently advancing multiple novel immunotherapies for the treatment of cancer.

To learn more about Orionis Biosciences, visit http://www.orionisbio.com/

Contact:
Nikolai Kley, President and Chief Executive Officer
617-663-4882
https://www.linkedin.com/in/nikolai-kley-107b7853/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved